Recently I published the list Buy 15 Best Shares, according to Jim Simons’ Renaissance Technology In this article, we will look at where Novo Nordisk A/S (NYSE:NVO) buys against other best stocks, according to Jim Simons’ Renaissance Technologies.
Even after his death in 2024, billionaire investor and mathematician Jim Simons is known as hedge fund “QUANT KING” for his incredible success. Renaissance Technologyhis quantitative trading company based in New York. After years of researching the financial industry, Simons recognized the untapped potential of adopting quantitative analysis to exploit market inefficiencies. This insight led him to develop a data-driven investment strategy that analyzes market behavior using only statistical and mathematical models. Quant Genius predicted future inventory movements and produced impressive returns by identifying subtle, non-random patterns in financial data.
Although closed to outside investors, Renaissance flagship Jim Simons’ secret medallion hedge fund has produced groundbreaking results since its founding. The medallion fund was raked with impressive returns of 56.6% and 74.6% during the DOT-COM crash of the early 2000s and the global financial crisis of 2007-2011. The fund has maintained a substantial annual revenue of 31.5% since its first two years of operation. At the time of his death, Simons was worth $31.4 billion, ranking him as the richest individual in the world thanks to the strong market performance of the Medallion Fund and Renaissance.
Read again: Billionaire David Einhorn’s 10-share pick holds a big boost and Billionaire Michael Pratt’s 10-share pick has great reflux potential.
Renaissance Technologies’ computer-driven powerhouse has gotten off to a great start after a fantastic performance in 2024. Renaissance’s institutional diversity Alpha Fund won 9.05% in February, continuing to score an impressive 2024 return of 15.6% since its arrival in 2021. 11.85% in the first two months of 2025. Both funds are permitted to maintain a substantial individual equity position in addition to managing risk using stock index futures and options. However, the company warns that it may be difficult to release these significant shares immediately without affecting market prices.
On this list, as of the end of the fourth quarter of 2024, we selected stocks from Renaissance Technologies’ 13F portfolio. These stocks are also popular among elite hedge funds.
Why are hedge funds interested in the stocks they accumulate? The reason is simple. Our research shows that mimic the top stock picks of the best hedge funds can outperform the market. Quarterly Newsletter’s strategy was to select 14 small and large caps per quarter, returning 373.4% since May 2014, surpassing the benchmark by 218 percentage points (For more information, please see here).
An elderly couple who received insulin from a pharmacist represents the successful medicines of the healthcare company.
Renaissance Technology Q4 Stake: $715 million
Number of hedge fund holders: 64
Novo Nordisk A/S (NYSE: NVO) is a renowned global healthcare company focusing on the treatment of rare diseases, diabetes and obesity. With 48,000 workers spread across more than 168 countries, Novo Nordisk is well known for its medicines such as Wegovy, Rybelsus and Ozempic.
On May 7, BOFA Securities lowered its price target for Novo Nordisk A/S (NYSE:NVO) stocks from DKK 910 to DKK 910 to DKK 850 despite maintaining its stock purchase rating. In a call with analysts, Novo Nordisk said he was confident in the later inflections driven by several initiatives. The company will also implement a focused SG&A commercial strategy. Novo Nordisk’s guidance is based on the idea that Wegovy and Ozempic will benefit from the decline in compound semaglutide later this year. However, BOFA analysts noted that the company provides limited information on how these processes work, including capture rates, brand switching and the impact of inventory levels.
Overall, NVO 3rd place According to Jim Simons’ Renaissance Technology, it is on the list of the best stocks to buy. While acknowledging the potential of NVOs as an investment, our belief lies in the belief that some AI stocks offer higher returns and hold a greater commitment to doing so within a shorter time frame. There have been AI stocks that have risen since the beginning of 2025, and the popular AI stocks have lost around 25%. If you’re looking for AI stocks that are more promising than NVOs but are trading below 5 times the revenue, check out our report on this Cheapest AI stocks.
Read next: Best AI stocks to buy now and According to the billionaire, 30 best stocks to buy now.
Disclosure: None. This article was originally published Insider Monkey.
